PLSE PULSE BIOSCIENCES, INC. Insider Trading

CEO Paul Laviolette's first open-market share purchase in 36 months: 15,000 shares while stock trades below 52-week high.

Paul Laviolette, the company's Chief Executive Officer, purchased shares on the open market for the first time in at least three years, a meaningful shift from his prior Form 4 activity which consisted exclusively of stock-based compensation transactions. The purchase occurred while the stock trades notably below its 52-week high, creating a meaningful distinction between what he received as part of his compensation package versus what he chose to buy with personal capital. The company remains unprofitable with a significant net loss in its most recent period, yet Laviolette is choosing to increase his ownership at current price levels rather than remain passive. As the CEO, his willingness to deploy personal capital into the business at this point in the stock's trajectory — after a multi-month decline — warrants attention from investors tracking leadership conviction, particularly given the rarity of this action in his filing history.

Director and 10% owner Robert Duggan purchases $13M in PLSE shares as stock trades below 52-week highs; 26th open-market buy in 36 months.

Robert Duggan, a director and major shareholder, has committed roughly $13 million to acquire shares at prices between the 52-week low and current levels, expanding his position significantly. This represents his 26th open-market purchase over the past three years—an unbroken pattern of accumulation with no offsetting sales. Duggan's prior purchases at this company have produced mixed near-term results (four of his previous five buys saw initial gains, but all five trades ultimately declined over a longer timeframe), suggesting his timing has been inconsistent. The company itself remains unprofitable with substantial operating losses, though it is generating meaningful revenue, meaning Duggan is buying a loss-making biotech business at a point when the stock sits notably below its 52-week highs. The scale and consistency of his purchasing activity—combined with his director status and substantial ownership stake—distinguishes this from routine insider trades, though his historical track record of poor long-term outcomes after prior purchases at this same company tempers the signal.

CEO Paul Laviolette's first open-market purchase: 15,000 shares in PLSE at $19.69, signaling personal conviction in biotech facing near-term profitability pressure.

Paul Laviolette, Pulse Biosciences' Chief Executive Officer, has made his first open-market purchase of company shares — a meaningful signal given that his prior Form 4 activity over three years consisted entirely of stock-based compensation transactions. By writing a personal check to acquire shares at an open-market price, he's moving beyond compensation vesting to actively putting capital at risk. The purchase comes as the stock trades notably below its 52-week high, and the company's financials show ongoing losses and limited revenue, making this a contrarian entry point for someone with direct knowledge of operations. This is the clearest available indicator of insider confidence when cash and stock comp are distinguished: Laviolette received equity through employment; now he's choosing to buy more. For a pre-revenue biotech or clinical-stage company, this kind of personal investment by the CEO carries weight precisely because insiders can afford to wait out downturns if they believe in the underlying assets.